Arovella Therapeutics Ltd
E4NA
Company Profile
Business description
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Contact
84 Hotham Street
Corporate One
PrestonVIC3072
AUST: +61 398636472
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
44
Stocks News & Analysis
stocks
Oracle shares are up 87% in 2025. Is it a buy?
Oracle’s cloud database business is riding the AI wave.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,137.80 | 14.90 | 0.16% |
CAC 40 | 7,872.02 | 41.91 | 0.54% |
DAX 40 | 23,611.33 | 84.28 | 0.36% |
Dow JONES (US) | 46,292.78 | 88.76 | -0.19% |
FTSE 100 | 9,223.32 | 3.36 | -0.04% |
HKSE | 26,159.12 | 185.02 | -0.70% |
NASDAQ | 22,573.47 | 215.50 | -0.95% |
Nikkei 225 | 45,493.66 | 447.85 | 0.99% |
NZX 50 Index | 13,109.81 | 26.73 | -0.20% |
S&P 500 | 6,656.92 | 36.83 | -0.55% |
S&P/ASX 200 | 8,845.90 | 14.30 | 0.16% |
SSE Composite Index | 3,821.83 | 6.74 | -0.18% |